To evaluate the elicitation and the duration of anti-SARS-Cov-2 neutralizing antibodies (nAbs) after BNT162b2 vaccination in subjects with Multiple Sclerosis (swMS) naïve or under therapy compared to Healthy Subjects (HS).

Questions have raised about anti-SARS-CoV2 vaccine efficacy in subjects under immunosuppressive/immunomodulatory therapies such as swMS. These therapies are often associated with qualitative and quantitative changes of the immune system, and thus may have implications on the efficacy of anti-SARS-CoV-2 vaccine due to a different elicitation of the immune response. The neutralizing capacity of vaccine-induced antibodies (Abs), as well as the duration of these nAbs is a fundamental issue to be addressed for the comprehension of how swMS respond to anti-SARS-CoV-2 vaccine.

At multivariable analysis, swMS showed a lower anti-RBD IgG production one month after vaccination with respect to HS. This was mainly due to a lower anti-RBD IgG production in swMS under anti-CD20, Fingolimod or Cladribine treatment.